Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

AIM: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). METHODS: A probabilistic Markov model (second-order Monte Carlo simulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginestal, Ricardo, Rubio-Terrés, Carlos, Morán, Olga Durán, Rubio-Rodríguez, Darío, Los Santos, Heidi De, Ordoñez, Cristina, Sánchez-Magro, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288949/
https://www.ncbi.nlm.nih.gov/pubmed/36705064
http://dx.doi.org/10.2217/cer-2022-0193
Descripción
Sumario:AIM: To analyze the cost–effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). METHODS: A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. RESULTS: CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF. CONCLUSION: CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.

Ejemplares similares